Urogen Pharma (NASDAQ:URGN - Get Free Report) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating in a report released on Monday, Marketbeat Ratings reports. The brokerage presently has a $50.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 236.25% from the stock's current price. HC Wainwright also issued estimates for Urogen Pharma's Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.43 EPS.
A number of other analysts have also issued reports on URGN. Oppenheimer reduced their price target on shares of Urogen Pharma from $36.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday, June 3rd. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Urogen Pharma in a research report on Thursday, June 12th. Guggenheim reissued a "buy" rating and issued a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. Finally, The Goldman Sachs Group reduced their price target on shares of Urogen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Urogen Pharma has a consensus rating of "Buy" and an average target price of $32.86.
Get Our Latest Stock Report on URGN
Urogen Pharma Price Performance
NASDAQ URGN traded up $1.63 on Monday, reaching $14.87. The company's stock had a trading volume of 3,965,606 shares, compared to its average volume of 1,030,493. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $18.15. The company has a debt-to-equity ratio of 4.77, a quick ratio of 5.47 and a current ratio of 5.65. The stock has a market cap of $685.66 million, a PE ratio of -4.68 and a beta of 0.40. The firm's 50 day moving average is $8.79 and its two-hundred day moving average is $10.10.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The business had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. As a group, sell-side analysts predict that Urogen Pharma will post -3.12 EPS for the current year.
Insider Buying and Selling
In related news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the sale, the insider now directly owns 153,378 shares in the company, valued at $1,130,395.86. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.10% of the company's stock.
Hedge Funds Weigh In On Urogen Pharma
Institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC lifted its stake in Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after acquiring an additional 5,140 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Urogen Pharma in the 4th quarter valued at approximately $59,000. Lazard Asset Management LLC bought a new stake in Urogen Pharma in the 4th quarter valued at approximately $67,000. GAMMA Investing LLC lifted its stake in Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after acquiring an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Urogen Pharma in the 4th quarter valued at approximately $101,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.
About Urogen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
